$3.64
0.14%
Downside
Day's Volatility :9.13%
Upside
9.0%
74.73%
Downside
52 Weeks Volatility :83.8%
Upside
35.92%
Period | Omeros Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -5.7% | 5.1% | 0.0% |
6 Months | -19.47% | 4.9% | 0.0% |
1 Year | 7.22% | 16.6% | 0.0% |
3 Years | -76.71% | 13.2% | -22.3% |
Market Capitalization | 234.7M |
Book Value | - $2.15 |
Earnings Per Share (EPS) | -3.32 |
PEG Ratio | -0.17 |
Wall Street Target Price | 43.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -26.32% |
Return On Equity TTM | -576.33% |
Revenue TTM | -30.0M |
Revenue Per Share TTM | -0.48 |
Quarterly Revenue Growth YOY | 14.899999999999999% |
Gross Profit TTM | -71.4M |
EBITDA | -185.3M |
Diluted Eps TTM | -3.32 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.02 |
EPS Estimate Next Year | -2.34 |
EPS Estimate Current Quarter | -1.14 |
EPS Estimate Next Quarter | -0.76 |
What analysts predicted
Upside of 1081.32%
Sell
Neutral
Buy
Omeros Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Omeros Corporation | -12.29% | -19.47% | 7.22% | -76.71% | -79.58% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Omeros Corporation | 1.43 | NA | -0.17 | -3.02 | -5.76 | -0.26 | NA | -2.15 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Omeros Corporation | Buy | $234.7M | -79.58% | 1.43 | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Omeros Corporation
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 29.9%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 145.9%
Ingalls & Snyder LLC
BlackRock Inc
Vanguard Group Inc
Stifel Financial Corp
D. E. Shaw & Co LP
Geode Capital Management, LLC
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Organization | Omeros Corporation |
Employees | 198 |
CEO | Dr. Gregory A. Demopulos M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.64
-8.08%
Keyarch Acquisition Corp
$3.64
-8.08%
Connexa Sports Technologies Inc
$3.64
-8.08%
Us Value Etf
$3.64
-8.08%
First Wave Biopharma Inc
$3.64
-8.08%
Global X Msci Next Emerging
$3.64
-8.08%
Fat Projects Acquisition Corp
$3.64
-8.08%
Capital Link Global Fintech
$3.64
-8.08%
Applied Uv Inc
$3.64
-8.08%